Renalytix PLC reported a rise in first-half revenue to $1.6 million, up from $1.3 million the previous year, while reducing its underlying EBITDA loss to $6.4 million from $7.2 million. However, the company now expects full-year sales to be around $4 million due to delays in converting healthcare-system integrations into revenue. Commercial test revenue slightly declined due to the complexity of electronic medical record (EMR) integrations, though life sciences revenue increased significantly. Renalytix is also in discussions for a national distribution deal with major US diagnostic firms to expand access to its kidney disease diagnostic product, kidneyintelX.dkd, without heavy commercial investment.
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Red Light Holland, after acquiring Filament Health, has expanded its capabilities in pharmaceutical-grade psilocybin development. Filament completed a shipment of its botanical psilocybin drug candidate, PEX010, to the European Union to support multi...
Wendy's is running a $1 promotion on small Classic Chocolate or Vanilla Frosty from July 20 to August 23, with early access for Wendy's Rewards members on July 19 in celebration of National Ice Cream Day. The offer is redeemable via the Wendy's app a...
Inseego Corp. will release its financial results for the second quarter of 2026 on August 5, after market close. The company will hold a conference call the same day to discuss the results and business outlook. Investors can access the earnings repor...
